Prometheus Biosciences IncNASDAQ RXDX Stock Report

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm is engaged in discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, such as inflammatory bowel disease (IBD). The firm's precision medicine platform Prometheus360, which includes gastrointestinal (GI) bioinformatics databases, to identify therapeutic targets and develop therapeutic candidates to engage the targets. Its product pipeline includes PRA023, PR600, PR300, PR1100, PR1800 and PR2100. The firm's lead product candidate PRA023, is an IgG1 humanized monoclonal antibody (mAb) designed to target both inflammation and fibrosis associated with IBD. The company has focused on developing PRA023 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).